Ruboxistaurin in New York Heart Failure Classification III-IV Patients
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of ruboxistaurin for its safety, tolerability, and
effectiveness in treating adult patients with heart failure. Patients will receive 1 dose of
oral ruboxistaurin.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati University of Tennessee